Latest news with #SudhirNagarajan
Yahoo
13 hours ago
- Business
- Yahoo
AlphaMeld Corporation and VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance to Transform Metabolic and Liver Disease Therapeutics
GUILFORD, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- AlphaMeld Corporation, a global frontrunner in AI-powered drug discovery, and VedTechBio Research Pvt. Ltd., an emerging biopharma technology innovator specializing in translational research and program execution, today announced a multi-program strategic partnership to accelerate the development of novel therapies for metabolic and liver diseases, including obesity and rare hepatic disorders. The alliance will jointly advance up to three first-in-class therapeutic programs targeting urgent, unmet clinical needs in high-burden disease areas. This collaboration uniquely combines AlphaMeld's AI-native drug discovery platform with VedTechBio's translational infrastructure to compress timelines, reduce risk, and enhance capital efficiency—delivering superior value over traditional and first-generation AI drug discovery models. AI-Driven Discovery—De-Risked by Design At the core of the partnership is the AlphaMeld™ Platform, a proprietary drug discovery engine that leverages large-scale datasets, generative AI, and causal inference to triangulate the ideal drug-target-disease profile with unmatched precision and speed. The platform maps directional and functional relationships among genes, targets, pathways, biomarkers, and disease phenotypes—enabling a mechanistically informed, evidence-based discovery process. This capability unlocks powerful insights for hypothesis generation, target prioritization, and biomarker alignment, accelerating the path from computational hit to clinical candidate. 'While many AI platforms provide scalability or automation, the AlphaMeld Platform was purpose-built for translatability and impact,' said Dr. Krishnan Nandabalan, Ph.D., Chairman and CEO of AlphaMeld Corporation. 'With VedTechBio as a complementary partner, we now integrate downstream translational rigor with upstream AI innovation—bridging the infamous 'valley of death' in early drug discovery.' Execution at Scale in India's Biotech Capital VedTechBio brings to the partnership robust discovery infrastructure, deep disease biology expertise, and a proven execution engine—positioning programs for rapid advancement from in silico to in vivo. 'At VedTechBio, we view AI not as a tool but as a force multiplier for scientific thinking,' said Sudhir Nagarajan, Founder and Managing Director of VedTechBio. 'With AlphaMeld, we can now systematically validate and scale promising assets with confidence and capital discipline. This is a blueprint for the next generation of biotech R&D,' he added. For more information, please visit A New Benchmark for Global Biotech Partnerships This alliance establishes a transcontinental innovation corridor—setting a new benchmark for AI-biotech collaborations by pairing deep tech from the U.S. with high-throughput R&D capabilities in India, all focused on high-burden, underserved indications. As competitors increasingly invest in AI without integrating translational capabilities, AlphaMeld and VedTechBio offer a fully integrated, end-to-end value chain—from data to clinic. About AlphaMeld Corporation Headquartered in Guilford, Conn., AlphaMeld Corporation is redefining drug discovery by combining cutting-edge AI, machine learning, and generative AI with deep biomedical expertise. The AlphaMeld Platform unlocks insights from petabytes of structured and unstructured biomedical data to design clinically actionable therapies with a higher probability of success. The company partners with biotech, pharma, and academic institutions globally to catalyze impactful innovation in high-value disease areas. Learn more at | LinkedIn: @alphameld Contact: Anita Ganjoo, Ph.D. VP, Corporate Communications aganjoo@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fashion Value Chain
21 hours ago
- Business
- Fashion Value Chain
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Dr. Ramkesh Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages Indias CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information
Yahoo
a day ago
- Business
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
